BET inhibition efficiently induces apoptosis in CTCL cells in vitro, and this is potentiated by HDAC inhibition, strongly suggesting this combinatorial therapy might benefit advanced CTCL patients, including those refractory to single agent therapy. Here, HDAC9 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.